Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer

doi:10.4251/wjgo.v15.i6.959

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3056)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1591

Figures (1-3)

223

Tables (1-1)

222

Sum=2138

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

146

Download

243

Sum=389

Publishing Process of This Article

Item

Count

Browse

105

Download

267

Sum=372

Jun 15, 2023 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Jun 15, 2023; 15(6): 959-972
Published online Jun 15, 2023. doi: 10.4251/wjgo.v15.i6.959

Full Size Figure Download Figure

Figure 2 Targeted therapies used in systemic treatment for biliary tract cancers. AKT: Protein kinase B; EGFR: Epidermal growth factor receptor; ERK: Extracellular signal-related kinase; FGFR: Fibroblast growth factor receptor; GTP: Guanosine triphosphate; IDH1: Isocitrate dehydrogenase 1; IDH2: Isocitrate dehydrogenase 2; MEK: Mitogen-activated protein kinase; mTOR: Mammalian target of rapamycin; NTRK: Neurotrophic tyrosine receptor kinase; PI3K: Phosphoinositide-3-kinase; PKD1: Polycystic kidney disease 1; RAF: Raf proto-oncogene; RAS: RAS proto-oncogene.

Citation: Leowattana W, Leowattana T, Leowattana P. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer. World J Gastrointest Oncol 2023; 15(6): 959-972
URL: https://www.wjgnet.com/1948-5204/full/v15/i6/959.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i6.959